Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,328 active trials222 approved drugs2,775 evidence items
- NCIt
- C4741
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,686 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | not yet recruiting | Early Phase 1 | 6 | Royan InstituteOTHER_GOV | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709585 | Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients(BE-MASTER) | not yet recruiting | Phase 2 | 124 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 |
| Jul 16, 2026 |
| clinicaltrials |
| NCT07164469 | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma | not yet recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07653438 | In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy(PulmoPrint) | not yet recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer(MORALE-HN01) | not yet recruiting | Phase 1 / Phase 2 | 18 | Glycyx TherapeuticsINDUSTRY | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704203 | Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy | not yet recruiting | — | 150 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704216 | Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer | not yet recruiting | — | 150 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704645 | The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 180 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705919 | DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07472790 | A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma | not yet recruiting | Phase 1 | 15 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07691515 | Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma(RAINBOW) | not yet recruiting | Phase 3 | 140 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07698080 | Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 2 | 60 | Hematology department of the 920th hospitalOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07699757 | HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion | not yet recruiting | Phase 1 | 258 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07701681 | Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 75 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702305 | Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP | not yet recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07703644 | Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients(CZA-TDM) | not yet recruiting | — | 60 | Sizhou FengOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07254793 | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT | not yet recruiting | Phase 1 | 94 | University of ArizonaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 96 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma(MORALE-MM) | not yet recruiting | Phase 1 / Phase 2 | 28 | John KirkwoodOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07697339 | HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 | 40 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07697716 | In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing(PRECISE-EGFR) | not yet recruiting | — | 30 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07697898 | TDLN-Guided Lymphadenectomy After Neoadjuvant Immunochemotherapy for ESCC | not yet recruiting | — | 400 | Tongji HospitalOTHER | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07698054 | Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer | not yet recruiting | Phase 2 | 130 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07698457 | Clinical Benefit of 18F-FET in Glioma. | not yet recruiting | Phase 3 | 36 | Primo Biotechnology Co., LtdINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07699172 | EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors | not yet recruiting | N/A | 10 | Bo WangOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07699640 | Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care(RAISN 2) | not yet recruiting | N/A | 171 | Heinrich-Heine University, DuesseldorfOTHER | 2 | Jul 13, 2026 | clinicaltrials |
| NCT07700121 | PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma(PICSTAT) | not yet recruiting | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07678593 | A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation | not yet recruiting | Phase 1 / Phase 2 | 222 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease(TIBEC) | not yet recruiting | Phase 1 / Phase 2 | 154 | National University Hospital, SingaporeOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695519 | SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer(SCARLET) | not yet recruiting | — | 196 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 2 | 64 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695896 | Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | not yet recruiting | — | 200 | Yanyan LiuOTHER_GOV | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia(R/R AL) | not yet recruiting | Early Phase 1 | 18 | Zhujiang HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07697040 | Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC | not yet recruiting | Phase 1 | 12 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07669363 | Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)(Aurora) | not yet recruiting | Phase 2 | 230 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07689292 | Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma(SKB264-Fru-GA) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07691450 | Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | not yet recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691632 | Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692360 | Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma(IL6-OSCC) | not yet recruiting | — | 38 | University of PaviaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692477 | Molecular Characterization of Tumor-Microenvironment Interactions to Predict Drug Resistance in Gastric and GEJ Adenocarcinoma(GASTROIMMUNE) | not yet recruiting | — | 250 | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07692906 | Multimodal Evaluation-Guided Surveillance-Intervention With Endoscopic Selective Neck Dissection for Post-Radiotherapy N3 Nasopharyngeal Carcinoma | not yet recruiting | N/A | 80 | Xuelei Ma MDOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07692919 | VIA Versus Colposcopy | not yet recruiting | — | 200 | Sohag UniversityOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT06050850 | Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL(NOURISH-ALL) | not yet recruiting | N/A | 20 | University of Kansas Medical CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 16, 2026source: clinicaltrials